Omega Therapeutics snags $85M for genomic medicine
July 31, 2020
Massachusetts-based Omega Therapeutics has raised $85 million in new financing. Founded in 2017, the preclinical-stage genomic medicine startup focuses on treating cancer, inflammation, and autoimmune, metabolic and rare genetic diseases without changing patients' nucleic acid sequences. The new round will help fund Omega's first in-human clinical trials.